Browse drugs

…ever, these studies did not employ suitable active comparators. Metformin is often prescribed as first-line therapy in T2DM management, w…

…CI −0.53 to 0.86 events per 1000 person-years) or compared with DPP-4is (HR 0.94; 95% CI 0.71 to 1.24, rate difference −0.18; 95% CI −0…

…ple with T2DM and established CVD to receive either the SGLT2i, empagliflozin, or placebo.5 To be eligible for this study, people had to meet…

…ease, chronic kidney disease, non-liver cancer, CCI, metformin, DPP-4i, CLP-1RA, sulfonylureas, thiazolidinediones, insulin, ACEI/ARB,…

…analyses were directionally consistent.Conclusion Postoperative GLP-1RA initiation, compared with DPP-4i initiation, was associated wit…

…e estimated the comparative effect of incretin-based therapies (GLP-1RA and dipeptidyl-peptidase-4 inhibitors (DPP-4i)) versus sodium-g…

…T-2is versus DPP-4is in type 2 diabetes and (2) SGLT-2is versus metformin monotherapy among subjects with a diabetes duration of <5 years…

…ted the true neuroprotective effects of GLP-1 RAs compared with metformin. This underscores the potential superiority of GLP-1 RAs and hi…